Built for Populations. Runs at the Level of One.
Full mechanistic simulation of your specific disease — your genetics, your biology, your treatment — to surface what data can show and support the clinical teams making decisions.
Running at the Level of One
Drug development builds for populations. Clinical guidelines are written for the median patient. But the patients who most need computational support are rarely median — they have rare diseases, complex polypharmacy, treatment-resistant conditions, or some combination of all three. The tools built for populations do not work well at n=1.
The same mechanistic engine that simulates clinical trials across thousands of virtual patients can run on a single person — their genetics, their exact disease stage, their current medications, their biomarkers, their comorbidities — and produce a mechanistic picture of what is working, what is not, and where the biological gaps are. This is data and insight, not clinical advice. The work OVIVO does supports the clinical teams making decisions. It does not replace them.
What the Simulation Can Surface
For a patient with a defined condition, treatment history, genetic profile, biomarkers, and comorbidities, OVIVO can produce the following — each with explicit uncertainty bounds and evidence grading.
Treatment Coverage Map
Which biological pathways in the disease are being addressed by the current regimen, and by how much. Which are not. A quantitative gap analysis — not a qualitative assessment — showing where the treatment landscape has room.
Repurposing Candidates
Approved drugs with pathway overlap in the patient's specific disease that are not in their current regimen. Surfaced for clinical teams to evaluate — with explicit uncertainty, evidence grades, and DDI assessment against existing medications already accounted for.
Safety & Interaction Modeling
Full polypharmacy simulation: concentration modeling for every drug in the regimen, drug-drug interaction quantification, toxicity risk scoring, and organ-specific burden assessment. Particularly relevant for patients on complex multi-drug regimens where interaction effects are difficult to characterize clinically.
Novel Compound Hypotheses
In cases where the gap analysis identifies uncovered mechanisms with no approved drug — and where the patient and their clinical team are exploring investigational options — the discovery engine can generate novel molecule hypotheses for discussion with academic or clinical research partners. This is available in select cases only, with HYPOTHESIS-grade evidence grading.
When This Applies
Precision medicine at n=1 is the most demanding application of the platform. It is most valuable in cases where the standard clinical pathway offers limited answers.
Rare and Ultra-Rare Disease
Where no approved disease-modifying therapy exists and natural history data is sparse, the platform's individual-level simulation provides signal that population-level tools cannot. The same engine that runs across thousands of virtual trial patients runs on one — and does not require a large published trial to anchor its predictions.
Treatment-Resistant Conditions
Where standard-of-care has been exhausted, partially contraindicated, or has produced inadequate response, a mechanistic simulation of what the disease is and is not responding to can surface biological rationale for alternative approaches — for clinical teams to evaluate and act on.
Complex Polypharmacy
Patients with multiple comorbidities on multi-drug regimens carry interaction risks that are difficult to characterize manually. The platform models the full regimen — every drug, every interaction, every organ-specific burden — in a single simulation that accounts for the patient's specific metabolizer phenotype and organ function.
Compassionate Use
Where patients and clinical teams are exploring every available option outside the standard pathway, a mechanistic gap analysis and repurposing screen can identify candidates worth discussing — grounded in published pharmacology, not speculation. This is a starting point for a clinical conversation, not a treatment plan.
For Clinical Teams
For physicians and specialists working with patients who have exhausted standard options — precision medicine engagements are bespoke research projects, conducted in partnership with the clinical team. Please describe the condition and context in your inquiry.
develop@ovivolabs.comFor Patients and Families
If you or someone you care for is navigating a rare, complex, or treatment-resistant condition and you are exploring what computational research might surface — reach out. Every engagement of this kind begins with an honest conversation about what the data can and cannot show.
media@ovivolabs.comFor Researchers and Advocates
For academic researchers, rare disease advocacy organizations, and patient communities interested in computational approaches to conditions with unmet therapeutic need.
media@ovivolabs.com